Alloptic Receives Patent For Multiple Wavelength TDMA Optical Network: related news

Alloptic Receives Patent For "Multiple Wavelength TDMA Optical Network"

LIVERMORE, Calif.--(BUSINESS WIRE)--Alloptic, a global leader in the development of RF over glass (RFoG) and passive optical networking (PON) solutions for CATV, telecom, and private network operators worldwide, today announced that it has been granted a patent for "Multiple wavelength TDMA optical network" technology in the United States (U.S. Pat. 7,386,236). This patent provides intellectual property protection to Alloptic for the simultaneous use of multiple wavelengths to increase bandwidth over a passive fiber optic network (PON).

Alloptic receives patent for multiple wavelength TDMA optical network

Alloptic, a developer of RF over glass (RFoG) and passive optical networking (PON) products for CATV, telecom, and private network operators, today announced it has been granted a patent for "Multiple wavelength TDMA optical network" technology in the U.S.

Alloptic Receives Japanese Patent For Point-To-Multipoint Passive Optical Network That Utilizes Variable-Length Packets

LIVERMORE, Calif.--(BUSINESS WIRE)--Alloptic, a global leader in the development of RF over glass (RFoG) and passive optical networking (PON) solutions for CATV, telecom, and private network operators worldwide, today announced that it has been granted a patent by the Japan Patent Office for "Point-To-Multipoint Passive Optical Network That Utilizes Variable-Length Packets" (No. 2002-546329284479). Fiber-to-the-Home and Fiber-to-the-Business PON systems carry variable-length IP or Ethernet packets, which often must be fragmented and encapsulated into fixed-length frames for transmission. This patent applies to the way in which that critical function occurs in popular PON technologies that are deployed not only in Japan, but also around the globe.

Alloptic Receives Japanese Patent for Point-To-Multipoint Passive Optical Network That Utilizes Variable-Length Packets

LIVERMORE, Calif. - (Business Wire) Alloptic, a global leader in the development of RF over glass (RFoG) and passive optical networking (PON) solutions for CATV, telecom, and private network operators worldwide, today announced that it has been granted a patent by the Japan Patent Office for

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Network firewall vendors

If you offer network firewall products or services, choosing the right network firewall vendor partner is crucial. Network firewalls have varying shapes, sizes and customizable functions, but they all perform the same vital task of maintaining network security. With such a wide selection of network firewalls, it's important to choose a product and vendor that's right for your customer's network. Our Partner Program Directory is designed to help you select the network firewall vendor most compatible with you and your customers' networks. Peruse the list of network firewall vendors here, then click through to view a standardized checklist of the benefits each networking vendor offers via its partner program.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. "This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P.

Alloptic receives Japanese patent for passive optical network that utilizes variable-length packets

fibresystems.org's regular newswire makes it easy to keep on top of all the important news and developments in the optical networking industry. Delivered every two weeks, it includes all published news and analysis articles. Sign up now to get your copy.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Elex Technologies Receives United States Patent for Evaluating Hyperdocuments with Neural Networks

Houston, TX (PRWEB) July 25, 2008 -- Elex Technologies, Inc. (ElexTek (http://www.elextek.com)), a Houston, Texas based software solutions and consulting company, announced today that the United States Patent and Trademark Office has issued ElexTek's neural network patent for evaluating hyperdocuments. The US Patent numbered 7,403,929 is entitled "Apparatus and methods for evaluating hyperdocuments using a trained artificial neural network."

Milpitas May Make Use Of Old Earthlink Wi-Fi Network - Google to recreate Mountain View network in Milpitas

Milpitas, California is one of those small cities that was excited to get a citywide wireless network from Earthlink a couple of years back and then had to agree to a return of the network when Earthlink’s plans collapsed earlier this year. When the city accepted the network back, its plan was to use it solely as a municipal network. However, a new agreement is pending which would once again offer free wi-fi to about 7000 users per month. The agreement would allow for the formation of a collaborative group called Silicon Valley Unwired which includes the city, Google and I-Net Solutions (the group that provides Wi-Fi for Mountain View in cooperation with Google). This non-profit group would work together to offer the network’s service at no additional cost to the city using the infrastructure put into place by Earthlink.

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Non-Disruptive Backups and Migrations Enhances European Patent Protection and Management

The European Patent Office grants European patents. The EPO carries out searches and substantive examinations on a steadily rising number of European patent applications and international applications filed under the Patent Cooperation Treaty. The European Patent Office (EPO) needed to support up to 60 million patents documents and 800,000 patents within a high availability and ultra resilient DB2 environment. The European Patent Office deployed BMC DB2 solutions to more effectively support its customers and the management of its patent applications.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,� said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Encore Networks Announces the Issuance of a U.S. Patent Relating to its Selective Layer Encryption for Broadband Satellite Networks

Encore Networks, a leading supplier of industrially hardened VPN based network security appliances, today announced that it has been granted a patent by the U.S. Patent and Trademarks Office under U.S. Patent Number 7,360,083. This patent relates to Encore’s innovative method for providing security solutions to aid protocol acceleration over satellite networks using Selective Layer Encryption (SLE). SLE is an encryption technology that securely connects satellite networks with terrestrial links as part of an end-to-end Virtual Private Network (VPN) solution.

Patent Office finds voice, calls for software patent sanity

The US Patent and Trademark Office is a convenient whipping boy for problems with the patent system. The USPTO famously approved the junk patents at the heart of the legal battle between Research in Motion and a patent-trolling firm called NTP. The USPTO belatedly recognized its mistake and began invalidating the patents, but didn't finish the job in time to save RIM from being forced to pay $612.5 million to avoid having its whole BlackBerry network shut down.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Search took 0.28 seconds.